Mast Cell Activation Syndrome (MCAS): A UK Clinical Overview

Mast cell activation syndrome (MCAS) is a condition that has moved from the fringes of specialist immunology into considerably wider clinical awareness over the past decade. For patients, that increased recognition has often been welcome, particularly for those who have spent years with diagnoses that do not adequately account for their symptom pattern.

For clinicians, it has created a more complicated picture, in which a genuine and treatable disorder exists alongside a contested diagnostic framework and a significant risk of both under- and over-diagnosis. To better understand this change, it is important to look at what MCAS actually is, how it is defined and diagnosed under current international criteria, what it typically looks and feels like, and how it is approached in a UK clinical setting.

What Are Mast Cells and Why Do They Matter?

Mast cells are immune cells found in virtually every vascularised tissue in the body, with particularly high concentrations in the skin, gastrointestinal tract, airways and connective tissue.¹ Their primary function is as sentinel immune cells, detecting potential threats, including allergens, pathogens and physical injury, and responding by releasing a range of chemical mediators stored within their granules.

These mediators include histamine, prostaglandins, leukotrienes, tryptase and a range of cytokines, and their release produces the local and systemic inflammatory responses that characterise allergic reactions and immune activation.² In MCAS, mast cell mediator release occurs inappropriately or excessively duirng recurrent episodes. An identifiable allergenic trigger is not always present. Importantly, MCAS can be classified as primary (clonal), secondary to another process such as allergy, or idiopathic. It should therefore not simply be defined by a normal number of mast cells or contrasted directly with mastocytosis, as mastocytosis can itself be associated with mast cell activation. ³

Because mast cells are distributed so widely throughout the body and release mediators that affect such a broad range of tissues, the resulting symptom pattern tends to be multisystemic and episodic, which is both its defining clinical characteristic and the primary reason it is difficult to diagnose.

What Does MCAS Feel Like?

The hallmark of mast cell activation syndrome is symptoms affecting two or more organ systems simultaneously, occurring in episodic flares that are often triggered by specific exposures and that tend to improve between episodes. ⁴ Skin involvement is reported in the large majority of patients and is frequently the first symptom to prompt clinical attention. This includes flushing, episodes of sudden redness and heat spreading across the face, neck and chest driven primarily by histamine and prostaglandin D2, alongside urticaria, angioedema, itching and dermatographism, the formation of raised wheals following light pressure on the skin.⁴

Gastrointestinal symptoms are also common, as the gut contains a high density of mast cells. These include abdominal cramping, nausea, bloating, diarrhoea and vomiting that can closely mimic irritable bowel syndrome, functional dyspepsia or gastroparesis, and that are frequently attributed to those conditions before a mast cell cause is considered.⁵ Cardiovascular symptoms including tachycardia, hypotension, palpitations and lightheadedness can occur, as are respiratory symptoms including nasal congestion, throat tightness and wheeze. Patients may also report neurological features including cognitive impairment, brain fog, headache and mood disturbance, although these are non-specific symptoms and are not, in isolation, diagnostic of MCAS.⁶

How Is MCAS Diagnosed?

The diagnosis of MCAS is one of the areas where the clinical literature remains contested, and it is important to be straightforward about this rather than presenting a simple algorithmic pathway that does not reflect the current state of the field.

Two principal sets of diagnostic criteria exist.

The Vienna or consensus-1 criteria, developed by Valent and colleagues in 2012 and widely used in specialist immunology, require three conditions to be met: recurrent, episodic systemic symptoms consistent with mast cell mediator release affecting at least two organ systems; objective laboratory evidence of mast cell mediator release, most commonly a rise in serum tryptase of at least 20% above the individual’s baseline plus 2 nanograms per millilitre, ideally measured within one to four hours of a symptomatic episode; and a clinically meaningful response to treatments targeting mast cell mediators or mast cell stabilisation.⁷

A second framework, consensus-2, proposed by Afrin and colleagues, applies less restrictive criteria and identifies a larger patient population.⁸

A 2026 review published in a peer-reviewed journal concluded that fears of overdiagnosis under consensus-2 criteria have not materialised, and that underdiagnosis under more restrictive criteria remains an important clinical problem. This remains an area of active debate, however, and the broader consensus-2 criteria have not been universally adopted by allergy and immunology specialists.⁸

Serum tryptase is currently the most widely accepted biomarker, but it has recognised limitations. In many patients being investigated with suspected MCAS, baseline tryptase is within the normal range, and the characteristic event-related rise can be difficult to capture unless blood is drawn in the acute phase of a flare.⁹ Additional urinary mediator tests including N-methylhistamine, urinary leukotriene E4 and prostaglandin metabolites may provide supportive evidence of mast cell activation in selected cases, particularly when collected around a symptomatic episode. However, these tests are less well standardised than serum tryptase, and interpretation requires care. ¹⁰

In the UK, there is no single national NHS pathway for mast cell activation syndrome. Access to specialist assessment varies significantly between regions. Some NHS allergy or immunology services assess patients with suspected mast cell disorders, while others specifically do not accept referrals for suspected MCAS unless there are features such as recurrent anaphylaxis or other objective evidence of mast cell activation. A structured private consultation that documents symptom patterns, identifies potential triggers and initiates appropriate testing can provide an alternative starting point for investigation where appropriate.

How Is MCAS Managed?

Management of MCAS is stepwise and individualised, because both the triggering factors and the predominant mediators vary between patients, and the treatment response reflects that variability.¹¹

The starting point is trigger identification and avoidance. Common physical triggers include:

• Heat
• Cold
• Friction
• Exercise
• Emotional stress

Dietary triggers vary between individuals. Some patients report improvement when specific food triggers are identified, and a short, structured low-histamine dietary trial may sometimes be considered, which includes reducing intake of fermented foods, aged cheeses, alcohol and certain processed foods; this reduces the overall mediator load for many patients and provides a useful baseline from which individual tolerances can be assessed. Long-term, unnecessarily restrictive diets should be avoided, with individual tolerance and nutritional adequacy taken into account.

Pharmacological management typically follows a layered approach.

H1 antihistamines (the type that block the effects of histamine on tissues including the skin, airways and brain, such as cetirizine or loratadine) are considered first-line. They address the histamine-mediated symptoms, including flushing, urticaria, itching and brain fog.

H2 antihistamines (the type that act primarily on the stomach and cardiovascular system, such as famotidine) are added to address gastrointestinal and cardiovascular manifestations. Leukotriene receptor antagonists such as montelukast are used where respiratory symptoms or prostaglandin-driven features are prominent.

Mast cell stabilisers including sodium cromoglicate, used primarily for gastrointestinal symptoms, and ketotifen, which combines H1 antagonism with mast cell stabilisation, may also be considered where symptoms remain inadequately controlled on antihistamines alone, under appropriate clinical supervision. ¹²

No medications have been specifically licensed for mast cell activation syndrome, and all agents used are repurposed from their primary licensed indications in allergy, asthma or gastrointestinal disease.

A functional medicine approach to mast cell activation syndrome looks at the broader physiological context in which symptoms are occurring.

Nutritional deficiencies, gut dysbiosis, sleep, stress, systemic inflammation and immune dysregulation are all potential contributors to the environment in which mast cell overactivation is sustained, and identifying and addressing these alongside symptom-directed treatment forms the basis of a more comprehensive management plan.

What Does This Mean in Practice?

Mast cell activation syndrome is a real condition with a defined biological mechanism and a treatment approach that, in appropriately diagnosed patients, can produce meaningful improvement. It is also a diagnosis that requires careful clinical evaluation, genuine objective evidence, and a measured approach to the diagnostic criteria, because the symptom pattern it produces overlaps substantially with a large number of other conditions.

The appropriate response to a symptom picture that might suggest MCAS is a structured assessment, not a self-applied diagnosis. That assessment should document the symptom pattern systematically, identify whether it meets the systemic and episodic clinical criteria, consider relevant differential diagnoses and initiate appropriate laboratory investigation timed to symptomatic episodes where possible.

References